We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
-3.18%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$263M
AUM Growth
-$143M
Cap. Flow
-$77.6M
Cap. Flow %
-29.53%
Top 10 Hldgs %
50.47%
Holding
61
New
21
Increased
10
Reduced
9
Closed
20

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$22.6M
2
GBT
Global Blood Therapeutics, Inc.
GBT
+$12.5M
3
BMY icon
Bristol-Myers Squibb
BMY
+$11.9M
4
MRNA icon
Moderna
MRNA
+$10.6M
5
PASG icon
Passage Bio
PASG
+$9.43M

Top Sells

Rank Stock Value
1
AMRN
Amarin Corp
AMRN
+$20.6M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$18.6M
3
APLS
Apellis Pharmaceuticals
APLS
+$18M
4
BLUE
bluebird bio
BLUE
+$17.9M
5
XLRN
Acceleron Pharma
XLRN
+$14.2M

Sector Composition

Rank Sector Weight
1 Healthcare 92.71%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NGNE icon
51
Neurogene
NGNE
$640M
– –
-2,026
Closed -$499K
QURE icon
52
uniQure
QURE
$3.09B
– –
-138,425
Closed -$9.92M
SWTX
53
DELISTED
SpringWorks Therapeutics
SWTX
– –
-134,397
Closed -$5.17M
MRTX
54
PUT
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-210,000
Closed -$27.1M
ISEE
55
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-523,462
Closed -$4.49M
APTO
56
DELISTED
Aptose Biosciences, Inc.
APTO
– –
-1,164
Closed -$2.97M
CCXI
57
DELISTED
ChemoCentryx, Inc.
CCXI
– –
-186,238
Closed -$7.37M
XLRN
58
DELISTED
Acceleron Pharma
XLRN
– –
-267,676
Closed -$14.2M
KDMN
59
DELISTED
Kadmon Holdings, Inc.
KDMN
– –
-1,350,351
Closed -$6.12M
CNST
60
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
– –
-101,050
Closed -$4.76M
BHVN
61
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
– –
-187,242
Closed -$10.2M
1 2
3

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q1 2020 Portfolio in Review

As of Q1 2020, Logos Global Management held 61 positions worth $263M, down 35% from $406M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Logos Global Management withdrew a net $77.6M in Q1 2020, closing 20 positions and reducing 9 holdings. Its most notable exit was Amarin Corp, an estimated $20.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 82% a quarter earlier.

Against the trend, Logos Global Management opened a new position in AbbVie worth $20.2M.

  • Logos Global Management's largest Q1 2020 buy was AbbVie: 265,600 shares worth $20.2M.
  • Logos Global Management added most to Fulcrum Therapeutics in Q1 2020, an estimated $6.54M increase.
  • Logos Global Management's biggest Q1 2020 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $18.6M.
  • Logos Global Management fully exited Amarin Corp in Q1 2020, selling an estimated $20.6M.
  • Logos Global Management's ten largest holdings make up 50% of its $263M portfolio in Q1 2020.
  • Logos Global Management opened 21 new positions and closed 20 in Q1 2020.
  • Logos Global Management's portfolio value fell 35% quarter-over-quarter to $263M.

Based on Logos Global Management's 13F filing for Q1 2020, filed 15 May 2020.